Statute Details
- Title: Health Products (Clinical Research Materials) Regulations 2016
- Act Code: HPA2007-S332-2016
- Legislative Type: Subsidiary legislation (SL)
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health approval
- Authorising Act: Health Products Act (Cap. 122D), sections 71 and 72
- Commencement: 1 November 2016
- Current Version: Current version as at 27 Mar 2026
- Key Parts: Part 1 (General); Part 2 (Exceptions); Part 3 (Manufacture and Import); Part 4 (Supplies); Part 5 (Duties, records, reporting); Part 6 (Miscellaneous)
- Key Definitions: “clinical research”, “clinical research material”, “auxiliary CRM”, “institutional review board”, “administer”, “appropriate non-proprietary name”, and CTGT-related terms
What Is This Legislation About?
The Health Products (Clinical Research Materials) Regulations 2016 (“CRM Regulations”) set out a regulatory framework for how “clinical research materials” may be manufactured, imported, supplied, used, tracked, and reported in the context of clinical research involving human subjects in Singapore. In practical terms, the Regulations aim to ensure that products used in clinical research—whether investigational therapeutic products, placebos, or certain cell, tissue and gene therapy products—are handled in a way that protects research subjects and supports regulatory oversight.
The Regulations sit under the Health Products Act and operate alongside other Singapore research and healthcare regulatory regimes. They do not replace the need for ethical review and research governance (for example, via an institutional review board), but they provide product-focused controls: permissions and notifications for import/export, restrictions on supply, labelling expectations, traceability and recordkeeping duties, and safety reporting and recall mechanisms.
For practitioners, the most important takeaway is that the CRM Regulations treat clinical research materials as a distinct category of regulated “health products” for which specific compliance obligations apply across the lifecycle—before a product enters Singapore, while it is distributed and administered to subjects, and after adverse events or defects are identified.
What Are the Key Provisions?
1) Definitions and scope: what counts as a “clinical research material”. Section 2 is foundational. It defines “clinical research” as research involving human beings (whether or not a regulated clinical trial). It defines “clinical research material” as certain health products manufactured, imported, or supplied for the purpose of being used in clinical research by way of administration to a subject in accordance with the protocol. The definition includes, among other things: (a) a therapeutic product; (b) specified CTGT products (cell, tissue and gene therapy products) depending on their classification and notice status under the CTGTP Regulations; (c) a placebo; and (d) auxiliary materials used for the needs of the research but not as the material to be tested or used as a reference (the Regulations use the term “auxiliary CRM”).
It also defines key operational terms such as “administer” (broadly covering oral administration, injection or other introduction into the body, and external application), and “appropriate non-proprietary name” (linking to international non-proprietary names or specified monographs). These definitions matter because they determine whether a product is within the Regulations and which compliance steps apply.
2) Exceptions and regulatory gateways for import/export and supply. Part 2 addresses when the general prohibitions or controls under the Health Products Act do not apply, or when specific permissions/notifications are required. Section 3 provides “exceptions from Act” for certain activities relating to clinical research materials. Section 4 requires notification of import of clinical research materials. Section 5 introduces an approval requirement for import of consignments containing psychotropic substances, reflecting heightened risk controls for controlled medicines. Section 6 provides approval for export of consignments of certain clinical research materials, indicating that outbound movement is also regulated. Section 7 requires notification of supply of clinical research material by the manufacturer.
3) Manufacture and import controls. Part 3 contains Section 8: manufacture and import of clinical research materials. While the extract provided does not reproduce the full text of Section 8, the structure of the Regulations indicates that the HSA expects compliance with specified standards and conditions for manufacturing and importing clinical research materials. In practice, lawyers advising sponsors, manufacturers, and importers should assume that Section 8 is the compliance “hub” that ties together permissions, quality expectations, and the ability to lawfully bring clinical research materials into Singapore for use in human research.
4) Supply restrictions and labelling. Part 4 regulates how clinical research materials may be supplied. Section 9 requires that supply be only as clinical research material, preventing diversion into ordinary commercial channels. Section 11 restricts supply to a subject of prescription-only or pharmacy-only medicine (as clinical research material) to appropriate circumstances. Section 12 addresses supply to a subject by administration of prescription-only medicine, which is relevant where the medicine is administered by a healthcare professional rather than directly dispensed. Section 13 requires supply of clinical research material properly labelled, which is critical for subject safety, protocol adherence, and traceability. Labelling requirements typically interact with the “appropriate non-proprietary name” concept and with the need to distinguish investigational products, placebos, and auxiliary materials.
5) Lifecycle duties: dealing, traceability, records, adverse event reporting, defects, and recall. Part 5 is the most operationally significant for compliance teams. Division 1 begins with Section 14: dealing with clinical research materials. This is the general conduct rule—how holders and handlers may store, handle, transfer, and otherwise “deal” with clinical research materials in the course of clinical research.
Section 14A imposes a specific duty to maintain a system of traceability for a CTGT product. This reflects the complexity and high-risk nature of cell, tissue and gene therapy products, where chain-of-custody, batch integrity, and the ability to trace materials are essential for safety investigations and regulatory follow-up.
Division 2 then requires keeping of records. Sections 15 to 18 cover: (a) records of manufacture; (b) records of receipt and supply; (c) records of dealings with clinical research materials; and (d) production of and time for keeping of records. For practitioners, the practical message is that recordkeeping is not optional and must be capable of being produced to the Authority when required. The “time for keeping” provision is particularly important for retention schedules and for aligning with sponsor archiving policies.
Division 3 addresses safety and regulatory action. Section 19 requires notifications of unexpected serious adverse drug reactions. Section 19A imposes a duty to report defects. Section 20 provides for recall of clinical research material. Together, these provisions create a safety net: once adverse reactions or defects are identified, there are legal duties to notify and, where necessary, remove products from use through recall mechanisms. Lawyers should treat these as compliance triggers that require rapid internal escalation, documentation, and coordination with the sponsor, investigators, and the HSA.
6) Certificates of standards and enforcement/offences. Part 6 includes Section 21 (certificate of manufacturing standard) and Section 22 (certificate of distribution standard). These provisions indicate that the Authority expects formal attestations about quality and distribution practices for clinical research materials. Section 23 sets out enforcement requirements, and Section 24 provides offences. While the extract does not detail the offence provisions, the presence of these sections signals that non-compliance can lead to criminal or regulatory consequences, reinforcing the need for robust compliance systems.
How Is This Legislation Structured?
The CRM Regulations are organised into six parts:
Part 1 (General) contains the citation/commencement and definitions that determine the scope of the Regulations.
Part 2 (Exceptions) sets out when activities relating to clinical research materials are exempted from the general Health Products Act regime, and it introduces key notification and approval steps for import/export and manufacturer supply.
Part 3 (Manufacture and Import) provides the core rule for how clinical research materials may be manufactured and imported lawfully.
Part 4 (Supplies) restricts supply to the correct purpose (clinical research), regulates supply to subjects in relation to prescription-only/pharmacy-only medicines, and requires proper labelling.
Part 5 (Duties) is divided into three divisions: (i) dealing and traceability (including CTGT traceability); (ii) records (manufacture, receipt/supply, dealings, retention and production); and (iii) reports to the Authority (unexpected serious adverse drug reactions, defects, and recall).
Part 6 (Miscellaneous) includes certificates of standards, enforcement requirements, and offences.
Who Does This Legislation Apply To?
The Regulations apply to persons who manufacture, import, supply, distribute, or otherwise “deal with” clinical research materials in Singapore for use in clinical research by administration to human subjects under a protocol. This typically includes sponsors, manufacturers, importers, distributors, and healthcare service providers involved in administering or handling the materials.
The Regulations also interact with the roles of research governance bodies. For example, the definition of “institutional review board” reflects the ethical and safety review function under Singapore’s biomedical research framework. However, the CRM Regulations themselves focus on product handling and regulatory reporting rather than ethics approval. In practice, compliance teams must coordinate between (i) ethics/IRB and research protocol requirements and (ii) HSA-facing product compliance obligations under these Regulations.
Why Is This Legislation Important?
For legal practitioners, the CRM Regulations are important because they create enforceable obligations across the clinical research product lifecycle. Unlike purely contractual or protocol-based duties, these are statutory duties that can trigger regulatory action, recall, and offences for non-compliance. This makes them central to risk management for sponsors and supply chain participants.
The Regulations also reflect Singapore’s approach to balancing innovation with subject protection. By requiring notifications and approvals for certain imports/exports (including psychotropic substances), imposing labelling and supply restrictions, and mandating traceability and recordkeeping, the Regulations reduce the risk of unsafe or unauthorised product use. The safety reporting provisions (unexpected serious adverse drug reactions and defects) ensure that the Authority can respond quickly to emerging risks.
From a practical standpoint, lawyers should advise clients to build compliance workflows that cover: (1) pre-import and pre-supply notifications/approvals; (2) labelling and distribution controls; (3) traceability systems (especially for CTGT products); (4) record retention and audit readiness; and (5) rapid reporting and recall decision-making when adverse events or defects occur. These steps are often where legal exposure arises—particularly when multiple parties (sponsor, manufacturer, importer, site/investigator) share responsibilities.
Related Legislation
- Health Products Act (Cap. 122D)
- Healthcare Services Act 2020
- Human Biomedical Research Act 2015
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (CTGTP Regulations)
- Medical Registration Act 1997
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Clinical Research Materials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.